Epilepsy (Adults) in Major Markets: Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2035

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$17995

This report covers the 7 major markets and provides an Excel-based forecast model for the epilepsy market through 2035.

GlobalData anticipates that the global adult epilepsy market will grow steadily during the forecast period, with 7MM sales expected to increase from $11.4 billion in 2025 to $17.8 billion in 2035, at a compound annual growth rate (CAGR) of 4.5%.

In 2025, the US contributed approximately $9.2 billion in drug sales, representing 80.4% of the total adult epilepsy market across the 7MM, driven by high branded prices, a wider array of branded options, and the largest diagnosed prevalent population among the seven markets. The 5EU contributed approximately $1.8 billion, accounting for 15.8% of the total market, with Germany and the UK the largest individual contributors. Japan contributed approximately $429.4 million, representing 3.8% of the total market. By 2035, the US share is expected to rise further to 82.9% of global sales, while Japan's share is expected to fall to 2.8%, reflecting its markedly slower growth trajectory and fewer drug launches.

Scope

Overview of epilepsy, including epidemiology, symptoms, diagnosis, and disease management.

Annualized epilepsy market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2025 to 2035.

Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the migraine therapeutics market.

Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for migraine treatment. The most promising candidates in late-stage development are profiled.

Analysis of the current and future market competition in the global epilepsy market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the 7MM epilepsy therapeutics market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM epilepsy therapeutics market in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

UCB
Lundbeck
SK Life Sciences
Eisai
Pfizer
Jazz Pharmaceuticals
Praxis Precision Medicines
Xenon Pharmaceuticals
Harmony Biosciences
Rapport Therapeutics
Biohaven
Encoded Therapeutics
Stoke Therapeutics

Table of Contents

1. Executive Summary

1.1 Market overview

1.2 Epilepsy therapeutics market will grow to $18.2 billion by 2035

1.3 Key players will maintain their competitive positions

1.4 Lack of effective treatments and disease-modifying options remain a key challenge in the epilepsy market

1.5 What do physicians think?

2. Introduction

2.1 Catalyst

2.2 Related reports

2.3 Upcoming reports

3. Disease Overview

3.1 Etiology and pathophysiology

– Etiology

– Pathophysiology

– Increased excitation

– Decreased inhibition

3.2 Classification or staging systems

4. Epidemiology

4.1 Disease background

4.2 Risk factors and comorbidities

4.3 Global and historical trends

4.4 7MM forecast methodology

4.5 Sources

4.6 Forecast assumptions and methods

4.7 Epidemiological forecast for epilepsy (2025–35)

– Active diagnosed prevalent cases of epilepsy

– Age-specific active diagnosed prevalent cases of epilepsy

– Sex-specific active diagnosed prevalent cases of epilepsy

– Active diagnosed prevalent cases of epilepsy by seizure type

– Diagnosed prevalent cases of Dravet syndrome

– Diagnosed prevalent cases of Lennox-Gastaut syndrome

4.8 Discussion

– Epidemiological forecast insight

– Limitations of the analysis

– Strengths of the analysis

5. Disease Management

5.1 Diagnosis and treatment overview

5.2 KOL insights on disease management

6. Current Treatment Options

6.1 Overview

7. Unmet Needs and Opportunity Assessment

7.1 Overview

7.2 Lack of effective treatments for epilepsy

7.3 Measures to improve earlier diagnosis and patient referral

7.4 Improving recruitment into clinical trials

8. R&D Strategies

8.1 Overview

– Novel mechanisms of action

– Cell and gene therapies

– Reformulations and NMEs within established mechanisms of action

8.2 Clinical trials design

– Design overview

– Patient populations

– Cell and gene trials

9. Pipeline Assessment

9.1 Overview

9.2 Promising drugs in clinical development

10. Pipeline Valuation Analysis

10.1 Overview

10.2 Competitive assessment

11. Current and Future Players

11.1 Overview

11.2 Deal-making trends

12. Market Outlook

12.1 Seven major markets

– Forecast

– Drivers and barriers – global issues

12.2 US

– Forecast

– Key events

– Drivers and barriers

12.3 5EU

– Forecast

– Key events

– Drivers and barriers

12.4 Japan

– Forecast

– Key events

– Drivers and barriers

13. Appendix

13.1 Bibliography

13.2 Abbreviations

13.3 Methodology

– Forecast methodology

13.4 Primary research – KOLs interviewed for this report

– KOLs

– Primary research – prescriber survey

13.5 About the authors

– Analyst

– Therapy Area Director

– Epidemiologists

– Vice President of Disease Intelligence

– Global Head of Pharma Research, Analysis, and Competitive Intelligence

About GlobalData

Contact Us

Epilepsy (Adults) in Major Markets: Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2035 standard reports
Currency USD
$17,995

Can be used by individual purchaser only

$53,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Pharmaceuticals
New
Global M&A Deals in H1 2026 - Top Themes by…
$495 | August 2026
Pharmaceuticals
New
Pharmaceutical Drug Development Annual Review 2025
$1,200 | August 2026
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Epilepsy (Adults) in Major Markets: Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2035 in real time.

  • Access a live Epilepsy (Adults) in Major Markets: Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2035 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.